Neuromodulation: the real frontier

Lenire (Neuromod) pairs sound through headphones with mild electrical stimulation of the tongue, ~30–60 min/day for 12 weeks. It earned an FDA De Novo authorization in 2023 — the first device of its kind. Its trials (TENT-A1/A2/A3) show most users improve, with a clean safety record. The honest caveats: the pivotal design couldn't use a true sham; the key TENT-A3 trial only beat sound-alone in moderate-to-severe tinnitus; the benefit is modest (a drop in handicap, not silence); it runs ~$4,000 out of pocket; and durability is under-studied. A reasonable option for motivated moderate-to-severe sufferers who understand the limits. Evidence ●●●○○

The University of Michigan device (Susan Shore) pairs tones with precisely-timed neck and face stimulation to target the exact brain circuit behind somatic tinnitus. Its 2023 randomized, double-blind crossover trial showed meaningful drops in tinnitus impact and loudness that persisted after treatment — the most rigorous bimodal result to date. Two catches: it's validated only for somatic (jaw/neck-modulated) tinnitus, and it's not yet FDA-cleared (perhaps late 2026 or later). Promising, but don't put life on hold waiting for it. Evidence ●●●○○

Repetitive transcranial magnetic stimulation (rTMS) shows small, inconsistent effects, and AAO-HNS recommends against it as routine care. Vagus-nerve stimulation paired with tones is an early, invasive proof-of-concept. Both are interesting and neither is ready for prime time. Evidence ●●○○○